drugset / Trial / NCT04220476
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Timeline
- Start
- 2020-03-04
- Primary completion
- 2025-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Comparator | Palbociclib | Small molecule | 125 mg | — |